Literature DB >> 28898713

Longitudinal trends in HbA1c and associations with comorbidity and all-cause mortality in Asian patients with type 2 diabetes: A cohort study.

Miyang Luo1, Wei Yen Lim1, Chuen Seng Tan1, Yilin Ning2, Kee Seng Chia3, Rob M van Dam4, Wern Ee Tang5, Ngiap Chuan Tan6, Richard Chen7, E Shyong Tai8, Kavita Venkataraman9.   

Abstract

AIMS: This study examined longitudinal trends in HbA1c in a multi-ethnic Asian cohort of diabetes patients, and the associations of these trends with future risk of acute myocardial infarction (AMI), stroke, end stage renal failure (ESRD) and all-cause mortality.
METHODS: 6079 participants with type 2 diabetes mellitus in Singapore were included. HbA1c measurements for the five years previous to recruitment were used to identify patterns of HbA1c trends. Outcomes were recorded through linkage with the National Disease Registry. The median follow-up for longitudinal trends in HbA1c was 4.1years and for outcomes was between 7.0 and 8.3years. HbA1c patterns were identified using latent class growth modeling, and associations with outcomes were analyzed using Cox proportional hazards models.
RESULTS: Four distinct HbA1c patterns were observed; "low-stable" (72·2%), "moderate-stable" (22·0%), "moderate-increase" (2·9%), and "high-decrease" (2·8%). The risk of comorbidities and death was significantly higher in moderate-increase and high-decrease groups compared to the low-stable group; the hazard ratios for stroke, ESRD, and death for moderate increase group were 3.22 (95%CI 1.27-8.15), 4.76 (95%CI 1.92-11.83), and 1.88 (95%CI 1.15-3.07), respectively, and for high-decrease group were 2.16 (95%CI 1.02-4.57), 3.05 (95%CI 1.54-6.07), and 2.79 (95%CI 1.97-3.95), respectively. Individuals in the moderate-increase group were significantly younger, with longer diabetes duration, and greater proportions of Malays and Indians.
CONCLUSIONS: Deteriorating HbA1c pattern and extremely high initial HbA1c are associated with increased risk of long-term comorbidities and death. Therapeutic interventions to alter longitudinal HbA1c trends may be helpful in reducing this risk.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glycemic control; HbA1c; Health care delivery; Type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28898713     DOI: 10.1016/j.diabres.2017.08.013

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  15 in total

1.  Longitudinal trends in HbA1c patterns and association with outcomes: A systematic review.

Authors:  Miyang Luo; Kristin Hui Xian Tan; Chuen Seng Tan; Wei Yen Lim; E-Shyong Tai; Kavita Venkataraman
Journal:  Diabetes Metab Res Rev       Date:  2018-05-22       Impact factor: 4.876

2.  Resistance Exercise Intensity is Correlated with Attenuation of HbA1c and Insulin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Authors:  Yubo Liu; Weibing Ye; Qian Chen; Yong Zhang; Chia-Hua Kuo; Mallikarjuna Korivi
Journal:  Int J Environ Res Public Health       Date:  2019-01-07       Impact factor: 3.390

3.  Cohort profile: the Singapore diabetic cohort study.

Authors:  Miyang Luo; Linda Wei Lin Tan; Xueling Sim; Milly Khiam Hoon Ng; Rob Van Dam; E Shyong Tai; Kee Seng Chia; Wern Ee Tang; Darren Ej Seah; Kavita Venkataraman
Journal:  BMJ Open       Date:  2020-05-30       Impact factor: 2.692

Review 4.  Population segmentation of type 2 diabetes mellitus patients and its clinical applications - a scoping review.

Authors:  Jun Jie Benjamin Seng; Amelia Yuting Monteiro; Yu Heng Kwan; Sueziani Binte Zainudin; Chuen Seng Tan; Julian Thumboo; Lian Leng Low
Journal:  BMC Med Res Methodol       Date:  2021-03-11       Impact factor: 4.615

5.  Diabetes-related lower extremity complications in a multi-ethnic Asian population: a 10 year observational study in Singapore.

Authors:  Tessa Riandini; Deanette Pang; Matthias P H S Toh; Chuen Seng Tan; Daveon Y K Liu; Andrew M T L Choong; Sadhana Chandrasekar; E Shyong Tai; Kelvin B Tan; Kavita Venkataraman
Journal:  Diabetologia       Date:  2021-04-22       Impact factor: 10.122

6.  The association between trajectories of risk factors and risk of cardiovascular disease or mortality among patients with diabetes or hypertension: A systematic review.

Authors:  Yuan Wang; Eric Yuk Fai Wan; Ivy Lynn Mak; Margaret Kay Ho; Weng Yee Chin; Esther Yee Tak Yu; Cindy Lo Kuen Lam
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

7.  Association of Glycemic Control Trajectory with Short-Term Mortality in Diabetes Patients with High Cardiovascular Risk: a Joint Latent Class Modeling Study.

Authors:  Sridharan Raghavan; Wenhui G Liu; Seth A Berkowitz; Anna E Barón; Mary E Plomondon; Thomas M Maddox; Jane E B Reusch; P Michael Ho; Liron Caplan
Journal:  J Gen Intern Med       Date:  2020-04-24       Impact factor: 5.128

8.  Impact of type 2 diabetes and microvascular complications on mortality and cardiovascular outcomes in a multiethnic Asian population.

Authors:  Jonathan Yap; Kamalesh Anbalakan; Wan Ting Tay; Daniel Ting; Carol Yim Cheung; Charumathi Sabanayagam; Ching-Yu Cheng; Tien-Yin Wong; Khung Keong Yeo
Journal:  BMJ Open Diabetes Res Care       Date:  2021-07

9.  Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project.

Authors:  Mengge Zhou; Jing Liu; Yongchen Hao; Jun Liu; Yong Huo; Sidney C Smith; Junbo Ge; Changsheng Ma; Yaling Han; Gregg C Fonarow; Kathryn A Taubert; Louise Morgan; Na Yang; Yueyan Xing; Dong Zhao
Journal:  Cardiovasc Diabetol       Date:  2018-11-27       Impact factor: 9.951

10.  Association of diabetes treatment with long-term glycemic patterns in patients with type 2 diabetes mellitus: A prospective cohort study.

Authors:  Miyang Luo; Chuen Seng Tan; Wei Yen Lim; Kee Seng Chia; Wern Ee Tang; E Shyong Tai; Kavita Venkataraman
Journal:  Diabetes Metab Res Rev       Date:  2019-01-10       Impact factor: 4.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.